SCHEMBL1945818

SCHEMBL1945818

Cc1cc(C)c(S(=O)(=O)NCc2c(-c3ccccc3)noc2C)c(C)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.72
NPSR1 Q6W5P4 1/20 0.72
PKM P14618 3/20 0.71
TDP1 Q9NUW8 1/20 0.64
NR3C2 P08235 2/20 0.51
NR3C1 P04150 1/20 0.51
GABRA5 P31644 1/20 0.49
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NR2F2 P24468 1/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PLA2G1B P04054 1/20 0.46
MAPT P10636 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
THRB P10828 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MCOLN3 Q8TDD5 1/20 0.44
MT-CO2 P00403 1/20 0.44
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1948069 0.84 ALDH1A1 (0.66) ALDH1A1NPSR1PKMTDP1NR3C2
SCHEMBL1948484 0.81 ALDH1A1 (0.90) ALDH1A1NPSR1PKMTDP1NR3C2
SCHEMBL1948067 0.79 ALDH1A1 (0.76) ALDH1A1NPSR1PKMTDP1GABRA5
SCHEMBL1946242 0.77 ALDH1A1 (0.80) ALDH1A1NPSR1PKMTDP1NR3C2
SCHEMBL1946175 0.76 ALDH1A1 (0.72) ALDH1A1NPSR1PKMTDP1GABRA5
SCHEMBL1945823 0.74 ALDH1A1 (0.75) ALDH1A1NPSR1PKMTDP1NR3C2
SCHEMBL1948804 0.73 ALDH1A1 (0.73) ALDH1A1NPSR1PKMTDP1GABRA5
SCHEMBL5960090 0.73 L3MBTL1 (0.72) ALDH1A1NR3C1LMNASMN1; SMN2NR2F2
SCHEMBL10072902 0.72 ALDH1A1 (0.61) ALDH1A1NPSR1PKMTDP1NR3C2
SCHEMBL1272834 0.71 ALDH1A1 (0.60) ALDH1A1NPSR1PKMTDP1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2011-06-02 US disclosed
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2011-06-02 US disclosed
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2011-06-02 US disclosed
EP-1807405-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AstraZeneca AB (SE) 2007-07-18 EP disclosed
WO-2006046914-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 ALDH1A1 2813/4885NPSR1 225/4885PKM 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.